Virtual Library

Start Your Search

Diego Diaz Garcia

Author of

  • +

    P50 - Small Cell Lung Cancer/NET - Real World Outcomes (ID 232)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P50.03 - Lung Neuroendocrine Tumors. 12-Years Experience of a Single Cancer Institution (ID 2109)

      00:00 - 00:00  |  Presenting Author(s): Diego Diaz Garcia

      • Abstract
      • Slides


      Lung neuroendocrine tumors (NETs) are an uncommon group of pulmonary neoplasms that are characterized by neuroendocrine differentiation and relatively indolent clinical behavior. Lung is the second most common frequently involved site. There are no data in Mexican or Latin American populations regarding the clinical and pathologic characteristics as well as the prognosis in patients with NETs.


      We performed a retrospective analysis in patients with diagnosis of lung NETs during 2007 to 2018 at the Instituto Nacional de Cancerología in Mexico City. Inclusion criteria were age 18 years or older, histopathologically confirmed diagnosis by central pathologist. Clinical and pathological characteristics were collected from medical records. The primary outcome was overall survival (OS). The study was approved by research and ethical committees.


      A total of 145 patients were included in the analysis. The median follow-up was 10.8 months. The median age was 61 years, most patients were male (58%), smoking history was present in 70%, 81% were ECOG 0-1. According to WHO classification, grade 3 tumors were the most common in 80% (116/145), grade 2 in 3.45% (5/145), and grade 1 in 16.55% (24/145) of patients. In grade 3 tumors, the median expression of Ki67 was 60%. Regarding to stage, 6.9% (10/145) were stage I, 9.66% (14/145) stage II, 19.31% (28/145) stage III, and 64.14% (93/145) stage IV. Chemotherapy was the most frequent treatment in 56.5% (82/145), chemoradiotherapy in 14.4% (21/145), surgery in 9.6% (14/145) and 19.3% received other treatments. The median OS was 23.1 months for the entire cohort. 1, 3 and 5-year OS rates were 45%, 25% and 18%, respectively (Fig. 1). Stage and WHO grade were independently associated with OS (Fig. 2). The 5-year OS rate for stage I, II, III and IV, were 52%, 37%, 28% and 8%, respectively (p=0.0002). The 3-year OS rate by grade were 58% for grade 1 and 2, and only 15% for grade 3, the 5-year OS rate for grade 3 lung NETs was 9% (p=0.0002).


      Clinical stage and WHO grade are the most important prognostic factors in lung NETs. This is the largest study that report clinical, pathological and prognostic features in patients with lung NETs in Latin America.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.